The Forte trial studied a double dose (40 mg) vs regular dose (20 mg) of Copaxone on relapses in 1155 relapsing-remitting MS patients over one year. The randomized, double-blind study was conducted at 136 centers in North America, Argentina, Europe and Israel.
The higher dose did not work better than the regular dose in reducing relapses. Patients on the regular 20 mg daily dose of Copaxone did well; 78% of patients remained relapse-free over the course of the year.
BY: Barry Singer, MD DATE: July 23, 2008 TOPIC: MS Research News